Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Letter titled “Treatment With Dupilumab for Refractory Cutaneous B-Cell Pseudolymphoma,”1 the second author’s surname was spelled “Duvicy” but should be “Duvic.” This article was corrected online on May 11, 2022.
Error in Author Surname. JAMA Dermatol. 2022;158(6):706. doi:10.1001/jamadermatol.2022.1933
© 2023
Artificial Intelligence Resource Center